Illumina Inc ILMN:NASDAQ

Last Price$304.72Cboe Real-Time Last Sale as of 2:42PM ET 7/17/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+2.42(0.80%)
Bid (Size)$304.62 (18)
Ask (Size)$304.75 (1)
Day Low / High$302.28 - 304.96
Volume830.5 K
 

View Biotechnology IndustryPeer Comparison as of 07/17/2019

 

Illumina Inc ( NASDAQ )

Price: $304.72
Change: +2.42 (0.80%)
Volume: 830.5 K
2:42PM ET 7/17/2019
 
 

Biogen Inc ( NASDAQ )

Price: $231.05
Change: -0.50 (0.22%)
Volume: 553.9 K
2:42PM ET 7/17/2019
 
 

Vertex Pharmaceuticals Inc ( NASDAQ )

Price: $178.57
Change: +2.41 (1.37%)
Volume: 384.6 K
2:41PM ET 7/17/2019
 
 

Regeneron Pharmaceuticals Inc ( NASDAQ )

Price: $301.49
Change: +3.12 (1.05%)
Volume: 320.9 K
2:42PM ET 7/17/2019
 
 

Alexion Pharmaceuticals Inc ( NASDAQ )

Price: $124.58
Change: +1.76 (1.43%)
Volume: 1.0 M
2:42PM ET 7/17/2019
 

Read more news Recent News

Insider Selling in Illumina (ILMN) Shares Continues
10:18PM ET 7/15/2019 MT Newswires

There was a substantial sale of shares of Illumina by an insider today, as indicated in a form 4 document filed with the SEC. One insider -- Jay T...

Dare Bioscience Names William Rastetter as Board Chairman
9:30AM ET 7/15/2019 MT Newswires

Dare Bioscience (DARE) said it appointed William Rastetter, a current member of its board of directors, as chairman of the board effective Jul. 11. The...

Illumina's Consensus Expectations for Q2, 2019, and 2020 Earnings Reduced
12:31AM ET 7/13/2019 MT Newswires

Earnings estimates for Illumina Inc's (NASDAQ:ILMN, Recent Price: 305.05) Q2 ending June 30, 2019, and the full year forecasts for 2019 and 2020 have been...

Insider Trends: Insider Adds to Selling Trend at Illumina
6:21PM ET 7/12/2019 MT Newswires

On Jul 10, 2019, Jay T Flatley, Director, reported a sale of 3,300 shares in Illumina (ILMN) for $1,242,450. Flatley has control over 276,616 company...

Company Profile

Business DescriptionIllumina, Inc. engages in the development and manufacture of integrated systems for the analysis of genetic variation and function. It operates through the Core Illumina and Consolidated Variable Interest Entity segments (VIE). The Core Illumina segments serve customers in the research, clinical and applied markets, and enable the adoption of genomic solutions. The Consolidated VIE segment includes activities of GRAIL and Helix. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA. View company web site for more details
Address5200 Illumina Way
San Diego, California 92122
Phone+1.858.202.4500
Number of Employees7,300
Recent SEC Filing07/12/20194
President, Chief Executive Officer & DirectorFrancis A. deSouza
Senior Vice President-Global Quality & OperationsRobert P. Ragusa
Chief Financial Officer & Senior Vice PresidentSam A. Samad
Chief Technology Officer & Senior Vice PresidentMostafa Ronaghi

Company Highlights

Price Open$302.30
Previous Close$302.30
52 Week Range$268.62 - 380.76
Market Capitalization$44.8 B
Shares Outstanding147.0 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement07/29/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings52.85
Earnings per Share$5.62
Beta vs. S&P 500N/A
Revenue$3.3 B
Net Profit Margin25.06%
Return on Equity23.47%

Analyst Ratings as of 07/05/2019

Buy
11
Overweight
2
Hold
4
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset